Written by Compared with pre-surgical (neoadjuvant) chemotherapy alone, adding perioperative immunotherapy—given before and after surgery—significantly improved event-free survival (EFS) in patients with resectable early-stage non-small cell lung cancer(NSCLC), according to researchers from The University of Texas MD Anderson Cancer Center.
Medical Xpress – latest medical and health news stories